What are the subtypes of juvenile idiopathic arthritis (JIA)?

Subtypes of Juvenile Idiopathic Arthritis

According to the International League of Associations for Rheumatology (ILAR) classification system, juvenile idiopathic arthritis is divided into seven distinct categories: systemic arthritis, oligoarthritis, rheumatoid factor (RF)-negative polyarthritis, RF-positive polyarthritis, psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis. 1, 2

The Seven ILAR Categories

1. Systemic Arthritis

• Characterized by arthritis accompanied by or preceded by fever of at least 2 weeks duration that is documented to be daily (quotidian) for at least 3 days 1
• May present with additional systemic features including evanescent rash, generalized lymphadenopathy, hepatomegaly, splenomegaly, or serositis 1
• Represents approximately 25.8% of JIA cases in some registries 3
• Recognized as having striking autoinflammatory features, particularly in the early disease phase 4

2. Oligoarthritis

• Defined as arthritis affecting 1-4 joints during the first 6 months of disease 1, 2
• Further subdivided into:
  • Persistent oligoarthritis: affects ≤4 joints throughout the disease course 5
  • Extended oligoarthritis: affects >4 joints after the first 6 months of disease 1, 5
• Most common subtype, representing approximately 32.9% of cases 3
• Patients with early-onset, antinuclear antibody (ANA)-positive oligoarticular JIA have the highest risk of developing chronic iridocyclitis 2

3. RF-Negative Polyarthritis

• Arthritis affecting ≥5 joints during the first 6 months of disease with negative rheumatoid factor testing 1, 2
• Requires RF testing to be negative on at least two occasions at least 3 months apart 2
• Represents a distinct pathogenic pathway compared to RF-positive disease 5

4. RF-Positive Polyarthritis

• Arthritis affecting ≥5 joints during the first 6 months of disease with positive rheumatoid factor 1, 2
• Requires RF positivity on at least two occasions at least 3 months apart 2
• Constitutes a distinct subgroup with poorer prognosis, necessitating more intensive management 6
• Clinically similar to adult rheumatoid arthritis 2
• Uveitis is very rare in this subtype 2

5. Psoriatic Arthritis

• Arthritis accompanied by psoriasis, or arthritis with at least two of the following: dactylitis, nail pitting or onycholysis, or psoriasis in a first-degree relative 1, 2
• May present with oligoarticular or polyarticular joint involvement 7
• Can develop active sacroiliac arthritis 7

6. Enthesitis-Related Arthritis

• Arthritis and enthesitis (inflammation at tendon-to-bone insertion sites), or arthritis or enthesitis with at least two of: sacroiliac joint tenderness and/or inflammatory lumbosacral pain, HLA-B27 positivity, family history of HLA-B27-associated disease, anterior uveitis, or onset in males over 6 years of age 1, 2
• Characterized by recurrent acute symptomatic iridocyclitis rather than chronic anterior uveitis 2
• Most likely to develop active sacroiliac arthritis 7

7. Undifferentiated Arthritis

• Arthritis that fulfills criteria in no category or in two or more of the above categories 1, 2
• May include patients who cannot be classified due to overlapping features 8

Clinical Application Considerations

Treatment Group Framework

For therapeutic decision-making, the American College of Rheumatology uses treatment groups rather than strict ILAR categories because there is minimal evidence to support differential treatment for many category distinctions 1:

• History of arthritis in ≤4 joints: includes persistent oligoarthritis and some cases of psoriatic, enthesitis-related, and undifferentiated arthritis 1
• History of arthritis in ≥5 joints: includes extended oligoarthritis, both RF-negative and RF-positive polyarthritis, and some cases of psoriatic, enthesitis-related, and undifferentiated arthritis 1
• Active sacroiliac arthritis: primarily enthesitis-related and psoriatic arthritis, but may include any ILAR category 7, 1
• Systemic arthritis with active systemic features (without active arthritis) 1
• Systemic arthritis with active arthritis (without active systemic features) 1

Critical Pitfall

Failing to specify the JIA subtype leads to selection of inappropriate pharmacologic regimens, delayed access to biologic agents, inadequate risk stratification for joint damage, and inability to apply evidence-based treatment algorithms 6. Documentation must include the specific ILAR category, number of joints involved at onset and currently, presence of risk factors (RF status, anti-CCP antibodies, joint damage), and current disease activity level using validated measures such as cJADAS-10 6.